Insights into a Rare Clinical Phenomenon: Isolated Native Valve Endocarditis After Prosthetic Valve Implantation

Selective Native Valve Endocarditis After TAVI and SAVI

Sujoy Khasnavis MD[1], Majd Alhuarrat MD[1], Caroline Patton MA[2],

Shaunak Mangeshkar MD[1], Robert Faillace MD[1], Michael Grushko MD[1]

[1]Jacobi-North Central Bronx Medical Center, Bronx NY

[2]Albert Einstein College of Medicine, Bronx, NY

Address for correspondence:

Sujoy Khasnavis 646-761-3081 sujoy.khasnavis@gmail.com

111 East 210th Street Bronx, NY 10467

Conflict of interest disclosure: The authors declare no conflict of interest

Funding disclosure: This research did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors

Ethics declaration: Not applicable

Word count: 1645

Isolated Native Endocarditis Prosthetic Valve Implantation

Key Points

Question: What are the incidence, associations, and outcomes of selective native valve endocarditis following prosthetic valve implantation?

Findings: This systematic review found that isolated native valve endocarditis was reported most frequently after transcatheter aortic valve implants and particularly in mitral valves. Infrequently, selective native endocarditis is also seen in right heart valves. Diabetes and pulmonary disease are associated with selective native endocarditis after transcatheter implants.

Meaning: The development of isolated native valve endocarditis should be closely screened for in diabetic and pulmonary patients with transcatheter aortic valve implants. This phenomenon needs further study in non transcatheter populations. Moreover, patients with this rare endocarditis require close long term follow up as delayed mortalities are higher than are early mortalities.

Abstract

This review outlines contributors, associations, management, and outcomes in isolated native valve endocarditis after prosthetic valve implantation. A systematic review was performed using four major databases. Isolated native valve endocarditis was compared to prosthetic valve endocarditis in number of cases, age of occurrence, gender distribution, comorbidities, pathogens, prosthetic valve type, left ventricular ejection fraction, treatment type, and mortality. Isolated native valve endocarditis comprised 18.2 % of valvular endocarditis cases after transcatheter implantation. Mean age of this cohort was 79.5 +- 5 years. It was observed in males more than females. Transcatheter implantation was performed majority by transfemoral route. Compared to transcatheter endocarditis, isolated native valve endocarditis was linked to diabetes (39.5 % vs

24.1 %, p = 0.001) and chronic obstructive pulmonary disease (29.4 % vs 19.5 %, p = 0.0157). It was less associated with chronic kidney disease (32.8 % vs 45.3 %, p = 0.012). Gram positive infection rates were comparable between the cohorts. Surgery was less frequent in the former cohort (6.7 % vs 24.3 %, p < 0.05). Mortalities were over 50% after 2 year follow up and linked to heart failure, renal failure, septic shock, and systemic embolism. Isolated native valve endocarditis makes up a measurable proportion of infective endocarditis cases after transcatheter implantation. It is associated with diabetes and pulmonary disease. Given the mortality rate and capacity of isolated native valve endocarditis to manifest on different valves, thorough cardiac evaluation should be considered if infective endocarditis is suspected after transcatheter implantation. Non-mitral isolated native valve endocarditis warrants further investigation.

Keywords: Isolated native valve endocarditis, transcatheter aortic valve implantation, prosthetic valve implantation, mitral endocarditis, right heart endocarditis

Abbreviations: IE = infective endocarditis, INVE = isolated native valve endocarditis, PVE = prosthetic valve endocarditis, PVI = prosthetic valve implant, TAVI = transcatheter aortic valve implant, TAVIE = transcatheter aortic valve implant endocarditis, SAVI = surgical aortic valve implant, SAVIE = surgical aortic valve implant endocarditis, AF = atrial fibrillation, DM = diabetes mellitus, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease

Introduction

Prosthetic valve endocarditis (PVE) is an established risk and complication of mechanical and bioprosthetic valve placement[1,2]. In general, infective endocarditis (IE) has a predilection for prosthetic valves over native valves given the nidus that the prostheses provide for bacterial attachment and infection[3,4]. PVE also carries a higher mortality rate than does native valve endocarditis. The incidence of native valve endocarditis subsequent to PVE has also been described and is known to carry a poorer prognosis than isolated PVE[4,8]. In the setting of a PVI, the development of isolated native valve endocarditis (INVE) without PVE is an unusual phenomenon. Select retrospective reviews have described INVE after PVIs[1,2,4,11]. Case reports have also described instances of mitral and aortic INVE in the setting of UTIs and atypical bacterial infections[5,6]. However, a comprehensive review of INVE has not been performed in prior studies. This review examines studies in literature which report on INVE after various PVIs. The review outlines the age groups, genders, comorbidities, pathogens, treatments, prosthesis types, cardiac function, and outcomes associated with INVE after PVI.

Methods

Search strategy

A systematic review of studies reporting INVE was performed across databases of Pubmed, Embase, Cochrane Library, and Web of Science. Search termsa encompassed PVI types including TAVI (transcatheter aortic valve implant) and SAVI (surgical aortic valve implant) as well as PVE and NVE. Table 1 shows the complete search criteria.

Definition of Valvular Endocarditis

IE was defined based on the modified Duke's criteria. Studies also had their own specific criteria for defining IE and these definitions were used to identify TAVIE (transcatheter aortic valve implant endocarditis), SAVIE (surgical aortic valve implant endocarditis), and INVE cases.

Study selection

Figure 1 shows the PRISMA strategy for screening and exclusion. All authors were aware of journal titles, journal authors, and sites where studies were done. No limits were placed on study date or design except that case reports, case series, editorials, and commentaries were excluded from data analyses. Non-English studies were excluded. Abstracts on outcomes/results/events after PVI were included. After screening abstracts, full texts were reviewed to identify cases of INVE. References in these studies were also examined for cases of INVE.

Data extraction

Data on incidence, age groups, genders, comorbidities, treatment types, pathogens, left ventricular ejections, follow up, and mortality rates were determined from included studies and IE after TAVR registry. All data are available in tables provided with manuscript. All authors contributed to acquisition of study data.

Assessment of risk of bias

Risk of bias assessment was performed for all studies included in the final cohort. Newcastle Ottawa Assessment Tool was utilized to carry out the assessment (Table 6).

Results

Study characteristics

The search yielded 952 studies after removal of duplicates in Covidence. In these 952 studies, abstracts that described the outcomes of PVI were identified and moved into full text review. Out of 196 full texts on PVI outcomes, 16 matched the criteria for INVE. These studies were manually reviewed for INVE populations from the same registries. References in these studies were also reviewed. Ultimately, INVE cases reporting non TAVIs and non SAVIs were excluded since very few cases were identified. INVE cases from 8 studies on TAVI and SAVI were included in the final analysis (Table 2). These studies comprised of retrospective reviews and complete prospective cohort analyses.

Risk of bias

Complete data was reported in 1 of the 8 studies; the remaining studies were missing data in specific categories marked as “unknown” in Tables 3 and 5. The INVE group was represented in all studies. The studies obtained patient and outcome information from review of medical

records. All studies assessed outcomes and ensured adequate follow-up. Follow-up time was sufficient for outcomes to occur in all cohorts. One study drew data from an international registry. The other studies drew data from single or dual hospital center databases.

INVE patient characteristics, management, and outcomes

INVE was observed in 119/655 (18.2 %) cases of valvular IE after TAVI. The mean age with standard deviation for the INVE group was 79.5 +- 5 years comparable to the TAVIE cohort. The valvular distributions of INVE were 87/119 (73.1%) on mitral valves and 32/119 (26.9%) on right heart valves. The specific valve locations of the latter were not identifiable.

Comorbidities in INVE and TAVIE were similar except the following. DM was present in 39.5 % INVE vs 24.1 % TAVIE ($p = 0.001$). COPD was present in 29.4 % INVE vs 19.5 % TAVIE ($p = 0.0157$). CKD was present in 32.8 % INVE vs 45.3 % TAVIE ($p = 0.012$).

Transfemoral access was utilized for TAVI in most INVE cases and mean left ventricular ejection fraction (LVEF) was 56 +- 2.7 %, similar to TAVIE. Corevalves were more frequently associated with INVE than TAVIE (54.7 % vs 44.6%, $p = 0.047$). In both INVE and TAVIE, cases were more frequent in males than females. Infections in INVE and TAVIE were from gram positive flora such as staphylococci, streptococci, and enterococci with comparable rates. INVE cases required surgery less frequently than did TAVIE cases (6.7 vs 24.3 %, $p < 0.05$).

TAVIE and INVE cases were followed for approximately 2 years. INVE mortalities were lower than TAVIE mortalities in hospital (21.0 % vs 32.3 %, $p = 0.016$). INVE mortalities were higher than TAVIE mortalities at follow up (30.3 % 20.5 %, $p = 0.016$). Mortality causal rates were similar except that INVE mortalities were more likely to be due to renal failure and

systemic emboli (21.9 % vs 12.5 %, p = 0.008 and 5.0 % vs 1.1 %, p = 0.004 respectively) (Table 4).

A similar analysis was attempted with the SAVI population. INVE was observed in 9/138 (6.5 %) cases of valvular IE after SAVI. The mean age with standard deviation for the SAVIE group was 59.9 ± 15.8 and for INVE group was 64.4 ± 3.8 years (Table 5). In two of the INVE cases, prior comorbidities and procedures were implicated including one case of tricuspid INVE associated with rheumatic disease and one case of mitral INVE associated with cardiac catheterization. However, a formal statistical analysis of the SAVI related INVE group was not possible given the small size of the INVE cohort and incomplete data on the SAVI population.

Discussion

INVE is a phenomenon that has been reported most often in mitral valves after TAVI. Cases of INVE in non mitral and non TAVI prostheses however have been reported less frequently; most associations and outcomes with INVE therefore have been in the context of native mitral valve with TAVI. Given this context, it is not surprising that the INVE cases in this review share many of the characteristics of TAVIE. It should be noted that certain comorbidities were more frequent in INVE than TAVIE, namely DM and COPD. These comorbidities were significantly associated with INVE possibly because of their high propensity for cardiopulmonary complications and chances of impacting heart valves nonselectively; these propositions would need to be examined in further investigations however. On the other hand, the weaker correlation with CKD is consistent with data showing that TAVIE is closely associated with CKD[19]. The significant association between self expanding Corevalve TAVIs and INVE can be explained by the fact that these Corevalves are in close proximity to other heart valves and therefore capable of infecting native valves, as has been suggested in prior studies[1]. However,

this correlation was weakly positive and requires investigation with a larger INVE cohort. As TAVIE presents a higher likelihood of serious complications after initial infection, the study supports the expected finding that mortalities were higher in hospital compared with INVE. The converse finding of lower mortality at follow up could be explained on the basis that the TAVIE population is smaller at follow up and thus has fewer mortalities compared to the INVE population. Alternatively, TAVIE is treated more aggressively initially with surgery and those who survive may be less likely to have complications leading to death as compared to conservative management in INVE. The higher rates of INVE mortality from renal failure and systemic emboli as compared to TAVIE have several plausible explanations. Among them could be that conservative management with antibiotics raises the likelihood of infection seeding into the vasculature to reach other systems. This could also be an incidental finding that requires a larger INVE base. While factors in TAVI with mitral INVE have been explored, factors in non TAVI and non mitral valve based INVE warrant further investigation. In our review, only 32 IE cases occurred as right heart INVE. Moreover, a review of SAVI related INVE yielded 9 cases occuring after various SAVI. These SAVI types included mechanical, biological, and homografts. Ultimately, a statistical analysis of SAVIE and SAVI related INVE was not possible due to the small number of cases in literature and lack of complete data, warranting further study. Although IV drug use has an established role in right heart endocarditis, the cases of right heart INVE in our study were not linked to drug use. These findings suggest that there are alternate mechanisms for non mitral INVE in the setting of both TAVIs and SAVIs.

Thus far, very few reviews have holistically examined the associations between INVE and the categories of interest in our study. Such reviews would have to identify many patients with this rare form of IE and acquire individual patient data pertaining to the categories of

interest. On the other hand, smaller studies have more individual patient data on these categories but not enough power to make significant associations due to smaller cohorts.

Limitations

Limitations in our study included the small size of the INVE population and their associated PVIs. Cases from only 16 studies fit the criteria for inclusion and most of them came from the IE After TAVI Registry. Thus the data was heavily skewed to create the impression that INVE is mostly a TAVI associated phenomenon.

Another limitation to our study was that we could not determine if studies excluded during full text review had unreported instances of INVE. As PVE is more common and studied more extensively than INVE, unreported INVE data could strengthen or weaken the associations in our study. Future research should be aimed towards acquiring more supplemental data from articles that explicity reported on INVE and from articles that did not explicity report on INVE.

A third limitation to our study was that our search strategy only looked at abstract titles in the decision to include or exclude articles. If any studies had included outcomes without explicity stating so in the title, these studies and their data were missed and would need to be examined more closely in future literature extractions.

Conclusion

INVE is a complication mostly reported with transfemoral TAVIs among elderly patients in their 70s. Gram positive skin pathogens are frequently involved in INVE and it is amenable to antibiotic therapy. Mortality in INVE is most commonly due to renal failure, embolism, heart failure, and bacteremia, with the former two more common in INVE than in TAVIE. The

incidence, contributors, associations, and outcomes of non-mitral INVE after TAVI as well as INVE after SAVI are less well established and warrant future study.

References

1. Panagides V, Del Val D, Abdel-Wahab M et al. Mitral Valve Infective Endocarditis after Trans-Catheter Aortic Valve Implantation. Am J Cardiol. 2022 Jun 1;172:90-97. doi: 10.1016/j.amjcard.2022.02.034. Epub 2022 Apr 3. PMID: 35387738.

2. Tinica G, Tarus A, Enache M et al. Infective endocarditis after TAVI: a meta-analysis and systematic review of epidemiology, risk factors and clinical consequences. Rev Cardiovasc Med. 2020 Jun 30;21(2):263-274. doi: 10.31083/j.rcm.2020.02.68. PMID: 32706214.

3. Lluri G, Levi DS, Miller E, Hageman A, Sinha S, Sadeghi S Incidence and outcome of infective endocarditis following percutaneous versus surgical pulmonary valve replacement. Catheter Cardiovasc Interv. 2018 Feb 1;91(2):277-284. doi: 10.1002/ccd.27312. Epub 2017 Sep 12. PMID: 28895275.

4. Mangner N, Leontyev S, Woitek FJ Cardiac Surgery Compared With Antibiotics Only in Patients Developing Infective Endocarditis After Transcatheter Aortic Valve Replacement. J Am Heart Assoc. 2018 Sep 4;7(17):e010027. doi: 10.1161/JAHA.118.010027. PMID: 30371173; PMCID: PMC6201426.

5. Pachirat O, Kaewkes D, Pussadhamma B, Watt G Corynebacterium diphtheriae Native Aortic Valve Endocarditis in a Patient With Prosthetic Mitral Valve: A Rare Presentation. Cardiol Res. 2018 Oct;9(5):314-317. doi: 10.14740/cr741w. Epub 2018 Oct 7. PMID: 30344830; PMCID: PMC6188043.
6. Akuzawa N, Kurabayashi M Native valve endocarditis due to Escherichia coli infection: a case report and review of the literature. BMC Cardiovasc Disord. 2018 Oct19;18(1):195. doi: 10.1186/s12872-018-0929-7. PMID: 30340526; PMCID: PMC6194693.
7. Yun JJ, Saleh OA, Chung JW et al. Cardiac Operations After Transcatheter Aortic Valve Replacement. Ann Thorac Surg. 2022 Jul;114(1):52-59. doi: 10.1016/j.athoracsur.2021.10.022. Epub 2021 Nov 17. PMID: 34800488.
8. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H et al. Infective endocarditis after transcatheter aortic valve implantation: results from a large multicenter registry. Circulation. 2015 May 5;131(18):1566-74. doi: 10.1161/CIRCULATIONAHA.114.014089. Epub 2015 Mar 9. Erratum in: Circulation. 2020 Jun 2;141(22):e879. PMID: 25753535.
9. Mangner N, Woitek F, Haussig S et al. Incidence, Predictors, and Outcome of Patients Developing Infective Endocarditis Following Transfemoral Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2016 Jun 21;67(24):2907-8. doi: 10.1016/j.jacc.2016.03.588. PMID: 27311532.
10. Mentias A, Girotra S, Desai MY et al. Incidence, Predictors, and Outcomes of Endocarditis After Transcatheter Aortic Valve Replacement in the United States. JACC Cardiovasc Interv.

2020 Sep 14;13(17):1973-1982. doi: 10.1016/j.jcin.2020.05.012. PMID: 32912457; PMCID: PMC7490767.

11. Solari S, Mastrobuoni S, De Kerchove L et al. Over 20 years experience with aortic homograft in aortic valve replacement during acute infective endocarditis. Eur J Cardiothorac Surg Dec 2016;50(6):1158-1164. 2016 Dec.
12. Sheikh AM, Elhenawy AM, Maganti M et al. Outcomes of surgical intervention for isolated active mitral valve endocarditis. J Thorac. Cardiovasc Surg Jan 2009;137(1):110-6. 2009 Jan.
13. Scisło P, Grodecki K, Wilimski R et al. Different types of endocarditis after transcatheter aortic valve implantation. Echocardiography Jun 2019;36(6):1132-1138. 2019 Jun.
14. Martínez-Sellés M, Bouza E, Díez-Villanueva P et al. Incidence and clinical impact of infective endocarditis after transcatheter aortic valve implantation. EuroIntervention Feb 2016;11(10):1180-7. 2016 Feb.
15. Martín-Dávila P, Fortún J, Navas E et al. Nosocomial endocarditis in a tertiary hospital: an increasing trend in native valve cases. Chest Aug 2005;128(2):772-9. 2005 Aug
16. Korem M, Israel S, Gilon D et al. Epidemiology of infective endocarditis in a tertiary-center in Jerusalem: a 3-year prospective survey. Eur J Intern Med Jul 2014;25(6):550-5. 2014 Jul.
17. Del Val D, Abdel-Wahab M, Mangner N et al. Stroke Complicating Infective Endocarditis After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology May 11 2021;77(18):2276-2287. 2021 May 11.
18. Croon SI, Angkasuwan A, van Straten AH et al. Surgical treatment and long-term outcome of aortic valve endocarditis with periannular abscess. Neth Heart J Jun 2020;28(6):345-353.
19. Regueiro A, Linke A, Latib A, et al. Association Between Transcatheter Aortic Valve Replacement and Subsequent Infective Endocarditis and In-Hospital Death. *JAMA.*

2016;316(10):1083–1092. doi:10.1001/jama.2016.12347.

Tables

Table 1. Search criteria in Pubmed, Embase, Cochrane, and Web of Science databases

Database	**PubMed**	
Line #	**Search Terms**	**Results**
1	“native valve endocarditis”[tiab] OR “NVE”[tiab] OR “native endocarditis”[tiab:~2]	1,625
2	ive” AND (“mitral valve endocarditis”[tiab] OR “aortic valve endocarditis”[tiab] OR id valve endocarditis”[tiab] OR “pulmonary valve endocarditis”[tiab] OR “pulmonic locarditis”[tiab] OR “infective endocarditis”[tiab] OR “infectious endocarditis”[tiab] OR “bacterial endocarditis”[tiab])	1,763
3	#1 OR #2	2,398
4	Heart Valve Prosthesis"[Mesh] OR "Heart Valve Prosthesis Implantation"[Mesh] OR osthetic valve”[tiab:~2] OR “valve replacement”[tiab] OR “transcatheter aortic valve nent”[tiab] OR “TAVR”[tiab] OR “transcatheter aortic valve implantation”[tiab] OR VI”[tiab] OR "transcatheter tricuspid valve replacement"[tiab] OR "TTVR"[tiab] OR eter pulmonary valve replacement”[tiab] OR “TPVR”[tiab] OR "transcatheter mitral cement”[tiab] OR "transcatheter mitral valve implantation”[tiab] OR “surgical aortic lacement”[tiab] OR “SAVR”[tiab] OR “surgical pulmonary valve replacement”[tiab] VR”[tiab] OR "surgical mitral valve replacement"[tiab] OR "surgical tricuspid valve replacement"[tiab] OR “homograft valve replacement”[tiab]	81,620
5	#3 AND #4	1,153
6	#5 NOT (case reports[pt] OR editorial[pt] OR letter[pt] OR comment[pt])	815
Filters	English-language only	680

Isolated Native Endocarditis Prosthetic Valve Implantation

rall search	((("native valve endocarditis"[Title/Abstract] OR "NVE"[Title/Abstract] OR "native endocarditis"[Title/Abstract:~2] OR ("native"[All Fields] AND ("mitral valve ndocarditis"[Title/Abstract] OR "aortic valve endocarditis"[Title/Abstract] OR "tricuspid valve rditis"[Title/Abstract] OR "pulmonary valve endocarditis"[Title/Abstract] OR "pulmonic valve endocarditis"[Title/Abstract] OR "infective endocarditis"[Title/Abstract] OR "infectious ndocarditis"[Title/Abstract] OR "bacterial endocarditis"[Title/Abstract]))) AND ("Heart Valve nesis"[MeSH Terms] OR "Heart Valve Prosthesis Implantation"[MeSH Terms] OR "prosthetic lve"[Title/Abstract:~2] OR "valve replacement"[Title/Abstract] OR "transcatheter aortic valve replacement"[Title/Abstract] OR "TAVR"[Title/Abstract] OR "transcatheter aortic valve implantation"[Title/Abstract] OR "TAVI"[Title/Abstract] OR "transcatheter tricuspid valve replacement"[Title/Abstract] OR "TTVR"[Title/Abstract] OR "transcatheter pulmonary valve replacement"[Title/Abstract] OR "TPVR"[Title/Abstract] OR "transcatheter mitral valve ent"[Title/Abstract] OR "transcatheter mitral valve implantation"[Title/Abstract] OR "surgical valve replacement"[Title/Abstract] OR "SAVR"[Title/Abstract] OR "surgical pulmonary valve replacement"[Title/Abstract] OR "SPVR"[Title/Abstract] OR "surgical mitral valve ent"[Title/Abstract] OR "surgical tricuspid valve replacement"[Title/Abstract] OR "homograft lacement"[Title/Abstract])) NOT ("case reports"[Publication Type] OR "editorial"[Publication ype] OR "letter"[Publication Type] OR "comment"[Publication Type])) AND (english[Filter])

Database	**Embase**	
Line #	**Search Terms**	**of Results**
1	‘native valve endocarditis’:ti,ab OR ‘NVE’:ti,ab OR ‘native endocarditis’:ti,ab	1,347
2	ND ('infective endocarditis'/mj OR ‘mitral valve endocarditis’:ti,ab OR ‘aortic valve endocarditis’:ti,ab OR ‘tricuspid valve endocarditis’:ti,ab OR ‘pulmonary valve rditis’:ti,ab OR ‘pulmonic valve endocarditis’:ti,ab OR ‘infective endocarditis’:ti,ab OR ‘infectious endocarditis’:ti,ab OR ‘bacterial endocarditis’:ti,ab)	2,746
3	#1 OR #2	3,406
4	e replacement'/exp/mj OR 'heart valve prosthesis'/mj OR 'aortic valve prosthesis'/mj 'mitral valve prosthesis'/mj OR 'pulmonary valve prosthesis'/mj OR 'tricuspid valve nesis'/mj OR ‘prosthetic valve’:ti,ab OR ‘valve replacement’:ti,ab OR ‘transcatheter aortic valve replacement’:ti,ab OR ‘TAVR’:ti,ab OR ‘transcatheter aortic valve tion’:ti,ab OR ‘TAVI’:ti,ab OR ‘transcatheter tricuspid valve replacement’:ti,ab OR R’:ti,ab OR ‘transcatheter pulmonary valve replacement’:ti,ab OR ‘TPVR’:ti,ab OR ‘transcatheter mitral valve replacement’:ti,ab OR ‘transcatheter mitral valve n’:ti,ab OR ‘surgical aortic valve replacement’:ti,ab OR ‘SAVR’:ti,ab OR ‘surgical pulmonary valve replacement’:ti,ab OR ‘SPVR’:ti,ab OR ‘surgical mitral valve acement’:ti,ab OR ‘surgical tricuspid valve replacement’:ti,ab OR ‘homograft valve replacement’:ti,ab	96,059
5	#3 AND #4	1,482
6	T ('conference abstract'/it OR 'conference paper'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it OR 'short survey'/it)	933
7	#6 NOT 'case report'/de	701

Isolated Native Endocarditis Prosthetic Valve Implantation

Filters	English-language only	585
rall search	lve endocarditis':ti,ab OR 'nve':ti,ab OR 'native endocarditis':ti,ab OR ('native' AND ('infective arditis'/mj OR 'mitral valve endocarditis':ti,ab OR 'aortic valve endocarditis':ti,ab OR 'tricuspid docarditis':ti,ab OR 'pulmonary valve endocarditis':ti,ab OR 'pulmonic valve endocarditis':ti,ab ve endocarditis':ti,ab OR 'infectious endocarditis':ti,ab OR 'bacterial endocarditis':ti,ab))) AND e replacement'/exp/mj OR 'heart valve prosthesis'/mj OR 'aortic valve prosthesis'/mj OR 'mitral hesis'/mj OR 'pulmonary valve prosthesis'/mj OR 'tricuspid valve prosthesis'/mj OR 'prosthetic ,ab OR 'valve replacement':ti,ab OR 'transcatheter aortic valve replacement':ti,ab OR 'tavr':ti,ab R 'transcatheter aortic valve implantation':ti,ab OR 'tavi':ti,ab OR 'transcatheter tricuspid valve ent':ti,ab OR 'ttvr':ti,ab OR 'transcatheter pulmonary valve replacement':ti,ab OR 'tpvr':ti,ab OR nscatheter mitral valve replacement':ti,ab OR 'transcatheter mitral valve implantation':ti,ab OR l aortic valve replacement':ti,ab OR 'savr':ti,ab OR 'surgical pulmonary valve replacement':ti,ab i,ab OR 'surgical mitral valve replacement':ti,ab OR 'surgical tricuspid valve replacement':ti,ab 'homograft valve replacement':ti,ab) NOT ('conference abstract'/it OR 'conference paper'/it OR itorial'/it OR 'letter'/it OR 'note'/it OR 'short survey'/it) NOT 'case report'/de AND [english]/lim	

tabase	**Cochrane Library**	
Line #	**Search Terms**	**# of Results**
1	“native valve endocarditis” OR “NVE” OR “native endocarditis”	63
2	AND (“mitral valve endocarditis” OR “aortic valve endocarditis” OR “tricuspid valve ocarditis” OR “pulmonary valve endocarditis” OR “pulmonic valve endocarditis” OR “infective endocarditis” OR “infectious endocarditis” OR “bacterial endocarditis”)	25
3	#1 OR #2	82
4	e prosthesis" OR “prosthetic valve” OR “valve replacement” OR “transcatheter aortic acement” OR “TAVR” OR “transcatheter aortic valve implantation” OR “TAVI” OR atheter tricuspid valve replacement" OR "TTVR" OR “transcatheter pulmonary valve t” OR “TPVR” OR "transcatheter mitral valve replacement” OR "transcatheter mitral alve implantation” OR “surgical aortic valve replacement” OR “SAVR” OR “surgical lmonary valve replacement” OR “SPVR” OR "surgical mitral valve replacement" OR "surgical tricuspid valve replacement" OR “homograft valve replacement”	4145
5	#3 AND #4	12
Filters	English-language only	12

Isolated Native Endocarditis Prosthetic Valve Implantation

base	Web of Science	
ine #	Search Terms	# of Results
1	“native valve endocarditis” OR “NVE” OR “native endocarditis”	1,437
2	” AND (“mitral valve endocarditis” OR “aortic valve endocarditis” OR “tricuspid valve ndocarditis” OR “pulmonary valve endocarditis” OR “pulmonic valve endocarditis” OR “infective endocarditis” OR “infectious endocarditis” OR “bacterial endocarditis”)	1,480
3	#1 OR #2	2,425
4	lve prosthesis" OR “prosthetic valve” OR “valve replacement” OR “transcatheter aortic eplacement” OR “TAVR” OR “transcatheter aortic valve implantation” OR “TAVI” OR ıscatheter tricuspid valve replacement" OR "TTVR" OR “transcatheter pulmonary valve ent” OR “TPVR” OR "transcatheter mitral valve replacement” OR "transcatheter mitral antation” OR “surgical aortic valve replacement” OR “SAVR” OR “surgical pulmonary placement” OR “SPVR” OR "surgical mitral valve replacement" OR "surgical tricuspid valve replacement" OR “homograft valve replacement”	49,772
5	#3 AND #4	708
lters	nguage only, document types: **Proceeding Paper**, **Editorial Material, Meeting Abstract, Letter, and Note were excluded**	566

Table 2. Summary of findings in final studies. Standard summary of findings for studies used in data extraction (n = 8)

	Study	Period	Study Population (#)	INVE Patients (#)	Incidence of IE (%)	Region	Design
TAVI E group	Panagides et al	June 2005 - Nov 2020	579	107	18.5 %	Europe, North America, and South America	Multicenter retrospective
	Yun et al	Jan 2012 - July 2020	10	2	20.0 %	Cleveland Clinic, Ohio	Single-center retrospective
	Mangner et al	June 2008 - Apr 2017	61	8	13.1 %	Heart Center Dresden, Germany	Single-center retrospective
	Scislo et al	Jan 2010 - Dec 2018	5	2	40.0 %	Medical University Warsaw, Poland	Single-center retrospective

SAVIE group	Martin Davila et al	Jan 1985 - Dec 1999	103	3	2.9 %	Ramon y Cajal Hospital Madrid, Spain	Single-center retrospective
	Solari et al	Jan 1990 - Dec 2014	5	1	20 %	St Luc's Hospital in Brussels	Single center cohort
	Korem et al	Jan 2009 -Oct 2011	22	4	18.2 %	Hadassah-Hospital, Jerusalem, Israel	Single center cohort
	Croon et al	Jan 1998 - Dec 2017	8	1	25 %	Catharina Hospital in Eindhoven, Netherlands	Single-center retrospective

Table 3. Summary of findings in TAVI groups + cumulative findings. Summary of categorical findings for TAVIE AND INVE populations per final study (n = 4)

Category	Panagides	Yun	Mangner	Scislo
Total size of TAVI group	20,006	59	110	311
Total # of IE cases	579	10	61	5
Total # of TAVIE cases	472	8	53	3
Total # of INVE cases	107	2	8	2
Mean age	78.5 ± 7.7	70	80.2 ± 5.5	81
TAVIE	79.7 ± 6.8	68.5	80.2 ± 5.5	76
INVE				
Gender	Male (253)	Male (6)	Male (31)	Male (2)
TAVIE	Male (60)	Male (1)	Male (5)	Male (1)
INVE				
Number of Comorbidities TAVIE				
DM	98	4	25	2
COPD	82	5	15	2
CKD	213	1	27	2
Coronary/Peripheral artery disease	0	2	39	2
AF	201	1	34	1
Hypertension	0	7	0	2
Stroke	38	2	5	0
Heart failure	0	0	30	0

Isolated Native Endocarditis Prosthetic Valve Implantation

Valvular regurgitation	81	6	0	2
Valvular stenosis	0	2	0	4
Inflammatory disease	0	0	0	0
Pulmonary embolism	2	0	0	0
Number of Comorbidities INVE				
DM	40	1	5	1
COPD	31	1	3	0
CKD	34	0	4	1
Coronary/Peripheral artery disease	0	0	6	0
AF	47	1	7	0
Hypertension	0	0	0	1
Stroke	10	0	1	0
Heart failure	0	0	6	0
Valvular regurgitation	25	1	0	0
Valvular stenosis	0	0	0	2
Inflammatory disease	0	0	0	0
Pulmonary embolism	2	0	0	0
TAVI access site per group				
TAVIE	397 (84.1%)	Unknown	47 (88.7 %)	2 (66.7 %)
Transfemoral	Unknown	Unknown	6 (11.3 %)	0 (0.0 %)
Transapical	Unknown	Unknown	0 (0.0 %)	1 (33.3 %)
Other				
	96 (89.7 %)	Unknown	7 (87.5 %)	2 (100.0 %)
INVE Transfemoral	Unknown	Unknown	1 (12.5 %)	0 (0.0 %)
Transapical	11 (10.3 %)	Unknown	0 (0.0 %)	0 (0.0 %)
Other				
LVEF	53.2 ± 13.0	59 %	53 ± 13	25-60 %
TAVIE	56.2 ± 11.8	59 %	53 ± 13	29-60 %
INVE				
Transcatheter valve type in TAVIE				
Corevalve self expanding	199	2	36	2
Edwards Sapien balloon expanding	273	6	17	0
Boston Scientific Lotus	0	0	0	1
Transcatheter valve type in INVE				
Corevalve self expanding	56	2	5	2
Edwards Sapien balloon expanding	51	0	3	0
Boston Scientific Lotus	0	0	0	0
Pathogens TAVIE				
Staphylococcus	186	4	20	2
Streptococcus	99	2	6	1
Enterococcus	130	2	21	1
Other	54	0	6	2
Pathogens INVE				
Staphylococcus	46	1	3	2
Streptococcus	27	0	1	0
Enterococcus	25	0	3	1
Other	8	1	1	0
Antibiotics TAVIE				
Vancomycin	21	Unknown	Unknown	3

Isolated Native Endocarditis Prosthetic Valve Implantation

Beta lactam/cephalosporin	439	Unknown	Unknown	1
Other	12	Unknown	34	3
Surgery TAVIE	102	8	19	1
Antibiotics INVE				
Vancomycin	8	Unknown	Unknown	1
Beta lactam/cephalosporin	99	Unknown	Unknown	1
Other	0	Unknown	Unknown	2
Surgery INVE	6	2	1	0
Follow up in years	2	1	1	3
Total deaths (in hospital + follow up)				
TAVIE	243	1	36	3
INVE	55	0	5	1

Cumulative findings for TAVI populations across 4 TAVI studies

Category of Interest	Number/% in TAVIE	Number/% in INVE
Total cases	536/655 (81.8 %)	119/655 (18.2 %)
Mean Age and SD (years)	78.6 +- 7	79.5 +- 5
Gender		
Male	292/536 (54.5 %)	67/119 (56.3 %)
Female	244/536 (45.5 %)	52/119 (43.7 %)

Isolated Native Endocarditis Prosthetic Valve Implantation

Comorbidity		
DM	129/536 (24.1 %)	47/119 (39.5 %)
COPD	104/536 (19.5 %)	35/119 (29.4 %)
CKD	243/536 (45.3 %)	39/119 (32.8 %)
Coronary/Peripheral artery disease	43/536 (8.1 %)	6/119 (5.0 %)
AF	237/536 (44.5 %)	55/119 (46.2 %)
Hypertension	9/536 (1.7 %)	1/119 (0.8 %)
Stroke	45/536 (8.4 %)	11/119 (9.2 %)
Heart failure	30/536 (5.6 %)	6/119 (5.0 %)
Valvular regurgitation	89/536 (16.7 %)	26/119 (21.8 %)
Valvular stenosis	6/536 (1.1 %)	2/119 (1.7 %)
Inflammatory disease	0/536 (0.0 %)	0/119 (0.0 %)
Pulmonary embolism	2/536 (0.4 %)	2/119 (1.7 %)
TAVI procedure access site		
Transfemoral	> 446/536 (> 83.7%)	> 105/119 (> 88.2 %)
Transapical	> 6/536 (> 11.1 %)	> 1/119 (> 0.8 %)
Other	> 1/536 (> 0.2 %)	> 11/119 (> 9.2 %)
LVEF	53 +- 12.7 %	56 +- 11.5 %
TAVI type + location if INVE		
Corevalve	239/536 (44.6 %)	+ mitral valve 46/119 (38.7 %) + right valve 19/119 (16.0 %)
Sapien	296/536 (55.2 %)	+ mitral valve 41/119 (34.5 %) + right valve 13/119 (10.9 %)
Lotus	1/536 (0.19 %)	0/119 (0.0 %)
Pathogen		
Staphylococcus	212/536 (39.6 %)	54/119 (45.4 %)
Streptococcus	108/536 (20.1 %)	28/119 (23.5 %)
Enterococcus	154/536 (28.7 %)	31/119 (26.0 %)
Other	62/536 (11.6 %)	9/119 (7.6 %)
Treatment type		
Antibiotics	406/536 (75.7 %)	111/119 (93.3 %)
Vancomycin	>20/536 (>3.7 %)	>9/119 (7.6 %)
Beta lactam/cephalosporin	>345/536 (64.3 %)	>100/119 (84.0 %)
Other	>46/536 (8.6 %)	>2/119 (1.7 %)
Surgery	130/536 (24.3 %)	8/119 (6.7 %)
Follow up period (years)	2	2
Mortalities in location and cause	173/536 (32.3 %) in hospital 0/536 (0.0 %) endocarditis 25/536 (4.7 %) septic shock 55/536 (10.3 %) heart failure 41/536 (7.6 %) renal failure 4/536 (0.7 %) systemic emboli 46/536 (8.6 %) bacteremia 2/536 (0.4 %) stroke	25/119 (21.0 %) in hospital 0/119 (0.0 %) endocarditis 1/119 (0.8 %) septic shock 6/119 (5.0 %) heart failure 11/119 (9.3 %) renal failure 3/119 (2.5 %) systemic emboli 4/119 (3.4 %) bacteremia 0/119 (0.0 %) stroke

	110/536 (20.5%) follow up 9/536 (1.7 %) endocarditis 16/536 (3.0 %) septic shock 33/536 (6.2 %) heart failure 26/536 (4.9 %) renal failure 2/536 (0.4 %) systemic emboli 24/536 (4.5 %) bacteremia 0/536 (0.0 %) stroke	36/119 (30.3 %) follow up 0/119 (0.0 %) endocarditis 3/119 (3.4 %) septic shock 10/119 (9.2 %) heart failure 15/119 (12.6 %) renal failure 3/119 (2.5 %) systemic emboli 5/119 (5.0 %) bacteremia 0/119 (0.0 %) stroke

Table 4. Categories with significant differences between TAVIE and INVE groups. Categories with significant differences between INVE and TAVIE after chi-square analyses with odds ratio (OR), relative risk (RR), P value, and confidence interval (CI).

Category of Interest	OR/RR	P value	CI
Comorbidity			
DM	OR = 2.00	0.001	1.38 - 3.19
COPD	OR = 1.73	0.016	1.09 - 2.66
CKD	OR = 0.59	0.012	0.38 - 0.90
TAVI type			
Corevalve	OR = 1.50	0.047	1.01 - 2.24
Intervention			
Surgery	RR = 0.28	< 0.05	0.14 - 0.56
Mortality location or cause			
Mortality in hospital	RR = 0.65	0.016	0.45 - 0.94
Mortality at follow up	RR = 1.47	0.016	1.07 - 2.02
Renal failure	RR = 2.08	0.008	1.08 - 4.00
Systemic emboli	RR = 4.50	0.004	1.48 - 13.7

Table 5. Summary of findings in SAVI groups + cumulative findings. Summary of categorical findings for SAVIE populations per final study (n = 4)

Category	Davila	Solari	Korem	Croon
Total size of SAVI group	Unknown	112	27	69
Total # of IE cases	103	5	22	8
Total # of SAVIE cases	100	4	18	7
Total # of INVE cases	3	1	4	1

Isolated Native Endocarditis Prosthetic Valve Implantation

Mean age	SAVIE	59.3 ± 17.9	58.5 ± 13.6	64.3 ± 7.1	58 ± 15
	INVE	68.7	58.5	64.2	58
Gender	SAVIE	Male (46)	Male (4)	Male (10)	Male (6)
	INVE	Male (3)	Male (1)	Male (3)	Male (1)
Number of Comorbidities SAVIE					
	DM	Unknown	Unknown	7	1
	COPD	Unknown	Unknown	0	1
	Coronary/Peripheral artery disease	Unknown	Unknown	0	1
	Hypertension	Unknown	Unknown	0	2
	Stroke	Unknown	Unknown	0	1
	Heart failure	Unknown	Unknown	10	1
	Malignancy	Unknown	Unknown	4	0
Number of Comorbidities INVE					
	DM	Unknown	Unknown	2	0
	COPD	Unknown	Unknown	0	0
	Coronary/Peripheral artery disease	Unknown	Unknown	0	0
	Hypertension	Unknown	Unknown	0	1
	Stroke	Unknown	Unknown	0	0
	Heart failure	Unknown	Unknown	1	0
	Malignancy	Unknown	Unknown	1	0
Surgical valve type in SAVIE					
Mechanical		0	0	0	2
Biologic					
	Bovine	0	0	0	5
	Porcine	0	0	0	0
	Homograft	0	4	0	0
Unknown		100	0	18	0
Surgical valve type in INVE					
Mechanical		0	0	0	0
Biologic					
	Bovine	0	0	0	1
	Porcine	0	0	0	0
Homograft		0	1	0	0
Unknown		3	0	4	0
Pathogens SAVIE					
	Staphylococcus	48	1	6	2
	Streptococcus	15	1	2	2
	Enterococcus	9	0	3	0
	Other	28	2	7	3
Pathogens INVE					
	Staphylococcus	2	1	1	1
	Streptococcus	0	0	1	0
	Enterococcus	1	0	1	0
	Other	0	0	1	0
Antibiotics SAVIE					
	Vancomycin	0	0	0	0
	Beta lactam/cephalosporin	0	0	0	0
	Other	71	1	14	0

Isolated Native Endocarditis Prosthetic Valve Implantation

Surgery SAVIE	29	3	4	7
Antibiotics INVE				
Vancomycin	0	0	0	0
Beta lactam/cephalosporin	0	0	0	0
Other	2	1	4	1
Surgery INVE	1	0	0	0
Follow up in years	8.5	20	0.5	10
Total deaths (in hospital + follow up)				
SAVIE	11 + 6	1 + 1	9 + 0	1 + 2
INVE	1 + 0	0 + 0	1 + 0	0 + 0

Cumulative findings for SAVI populations across 4 SAVI studies

Category of Interest	Number/% in SAVIE	Number/% in INVE	
Total cases	129/138 (93.5 %)	9/138 (6.5 %)	
Mean Age and SD (years)	59.9 ± 15.8	64.4 ± 3.8	
Gender			
Male	66/129 (51.2 %)	8/9 (88.9 %)	
Female	63/129 (48.8 %)	1/9 (11.1 %)	
Comorbidity			
DM	>8/129 (> 6.2 %)	>2/9 (< 22.2 %)	
COPD	>1/129 (> 0.8 %)	0/9 (0.0 %)	
Coronary/Peripheral artery disease	>1/129 (> 0.8 %)	0/9 (0.0 %)	
Hypertension	>2/129 (< 1.6 %)	>1/9 (< 11.1 %)	
Stroke	>1/129 (< 0.8 %)	0/9 (0.0 %)	
Heart failure	>11/129 (< 8.5 %)	>1/9 (< 11.1 %)	
Malignancy	>4/129 (< 3.2 %)	>1/9 (< 11.1 %)	
Surgical valve type in SAVIE + location if INVE			
Mechanical	2/129 (1.6 %)	+ mitral valve	0/9 (0.0 %)
Biologic		+ right valve	0/9 (0.0 %)
Bovine	5/129 (3.8 %)	+ mitral valve	1/9 (11.1 %)
Porcine	0/129 (0.0 %)	+ right valve	0/9 (0.0 %)
Homograft	4/129 (3.1 %)	+ mitral valve	1/9 (11.1 %)
Unknown	118/129 (91.5 %)	+ mitral valve	6/9 (66.7 %)
		+ tricuspid valve	1/9 (11.1 %)
Pathogen			
Staphylococcus	57/129 (44.2 %)	5/9 (55.6 %)	
Streptococcus	20/129 (15.5 %)	1/9 (11.1 %)	
Enterococcus	12/129 (9.3 %)	2/9 (22.2 %)	
Other	40/129 (31.0 %)	1/9 (11.1 %)	
Treatment type			
Antibiotics			

Isolated Native Endocarditis Prosthetic Valve Implantation

Vancomycin Beta lactam/cephalosporin Other Surgery	0 (0 %) 0 (0 %) 86/129 (66.7 %) 43/129 (33.3 %)	0 (0 %) 0 (0 %) 8/9 (88.9 %) 1/9 (11.1 %)
Follow up period (years)	7.8	6.4
Mortalities in location and cause	22/129 (17.1 %) in hospital only 10/129 (7.8 %) endocarditis 2/129 (1.6 %) septic shock 3/129 (2.4 %) heart failure 1/129 (0.8 %) renal failure 3/129 (2.4 %) systemic emboli 0/129 (0.0 %) bacteremia 3/129 (2.4 %) stroke 9/129 (7.0 %) follow up only 6/129 (4.7 %) endocarditis 0/129 (0.0 %) septic shock 0/129 (0.0 %) heart failure 0/129 (0.0 %) renal failure 3/129 (2.4 %) systemic emboli 0/129 (0.0 %) bacteremia 1/129 (0.8 %) stroke	2/9 (22.2 %) in hospital only 1/9 (11.1 %) endocarditis 0/9 (0.0 %) septic shock 0/9 (0.0 %) heart failure 0/9 (0.0 %) renal failure 0/9 (0.0 %) systemic emboli 0/9 (0.0 %) bacteremia 0/9 (0.0 %) stroke 0/9 (0.0 %) follow up only 0/9 (0.0 %) endocarditis 0/9 (0.0 %) septic shock 0/9 (0.0 %) heart failure 0/9 (0.0 %) renal failure 0/9 (0.0 %) systemic emboli 0/9 (0.0 %) bacteremia 0/9 (0.0 %) stroke

Table 6. Risk of bias assessment. Newcastle-Ottawa Scale Assessment of Cohort Studies

Assessment of quality of a cohort study – Newcastle-Ottawa Scale	
Selection (tick one box in each section)	

Isolated Native Endocarditis Prosthetic Valve Implantation

1. Representativeness of the intervention cohort a) truly representative of the average community-dwelling resident b) somewhat representative of the average community-dwelling resident c) selected group of patients, e.g. only certain socio-economic groups/areas d) no description of the derivation of the cohort	
2. Selection of the non intervention cohort a) drawn from the same community as the intervention cohort b) drawn from a different source c) no description of the derivation of the non intervention cohort	
3. Ascertainment of intervention a) secure record (eg health care record) b) structured interview c) written self report d) other / no description	
4. Demonstration that outcome of interest was not present at start of study a) yes b) no	
Comparability (tick one or both boxes, as appropriate)	
1. Comparability of cohorts on the basis of the design or analysis a) study controls for age, sex, marital status b) study controls for any additional factors (e.g. socio-economic status, education)	

Isolated Native Endocarditis Prosthetic Valve Implantation

Outcome (tick one box in each section)	
1. Assessment of outcome a) independent blind assessment b) record linkage c) self report d) other / no description	
2. Was follow up long enough for outcomes to occur a) yes, if median duration of follow-up >= 6 month b) no, if median duration of follow-up < 6 months	
3. Adequacy of follow up of cohorts a) complete follow up: all subjects accounted for b) subjects lost to follow up unlikely to introduce bias: number lost <= 20%, or description of those lost suggesting no different from those followed c) follow up rate < 80% (select an adequate %) and no description of those lost d) no statement	



Figure 1. Prisma Search. Search results generated from Covidence using PRISMA protocol. Breakdown of results from four databases and criteria used to acquire final studies for review (n = 16)